NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Sell
46
VRTX Quote, Financials, Valuation and Earnings
Last price:
$401.14
Seasonality move
:
6.89%
Day range:
$386.49 - $401.31
52-week range:
$377.85 - $519.88
Dividend yield:
0%
P/E ratio:
25.59x
P/S ratio:
9.73x
P/B ratio:
6.55x
Volume:
6M
Avg. volume:
1.7M
1-year change:
-0.74%
Market cap:
$102.3B
Revenue:
$9.9B
EPS (TTM):
-$1.99
Analysts' Opinion
-
Consensus RatingVertex Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 17 Buy ratings, 12 Hold ratings, and 2 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $498.37, Vertex Pharmaceuticals has an estimated upside of 25.42% from its current price of $397.27.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $325.00 representing 18.19% downside risk from its current price of $397.27.
Fair Value
-
According to the consensus of 31 analysts, Vertex Pharmaceuticals has 25.42% upside to fair value with a price target of $498.37 per share.
VRTX vs. S&P 500
-
Over the past 5 trading days, Vertex Pharmaceuticals has underperformed the S&P 500 by -12.6% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Vertex Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Vertex Pharmaceuticals has grown year-over-year revenues for 26 quarters straight. In the most recent quarter Vertex Pharmaceuticals reported revenues of $2.8B.
Earnings Growth
-
Vertex Pharmaceuticals has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Vertex Pharmaceuticals reported earnings per share of $4.01.
Enterprise value:
95.8B
EV / Invested capital:
6.13x
Price / LTM sales:
9.73x
EV / EBIT:
321.42x
EV / Revenue:
9.01x
PEG ratio (5yr expected):
1.13x
EV / Free cash flow:
-70.87x
Price / Operating cash flow:
29.55x
Enterprise value / EBITDA:
185.02x
Gross Profit (TTM):
$9.2B
Return On Assets:
-2.17%
Net Income Margin (TTM):
-4.52%
Return On Equity:
-2.89%
Return On Invested Capital:
-2.89%
Operating Margin:
40.82%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $8.7B | $9.7B | $10.6B | $2.5B | $2.8B | |
| Gross Profit | $7.7B | $8.5B | $9.2B | $2.2B | $2.4B | |
| Operating Income | $4.2B | $4.3B | $3.7B | $1.1B | $1.1B | |
| EBITDA | $4.2B | $4.5B | $517.7M | $1.2B | $1.3B | |
| Diluted EPS | $12.68 | $13.33 | -$1.99 | $3.97 | $4.01 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $7.5B | $8.9B | $12.3B | $14.7B | $9.8B | |
| Total Assets | $11.3B | $12.6B | $16.7B | $21.7B | $22.2B | |
| Current Liabilities | $2B | $1.9B | $2.6B | $3.6B | $4B | |
| Total Liabilities | $3.2B | $3.1B | $3.7B | $5.2B | $6.6B | |
| Total Equity | $8.1B | $9.5B | $13B | $16.5B | $15.6B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $4B | $4.4B | -$842.6M | $1.3B | $1.4B | |
| Cash From Investing | -$630.7M | -$2.1B | -$3.8B | -$117.7M | -$348M | |
| Cash From Financing | -$444.1M | -$402.2M | -$1.2B | -$165M | -$387.5M | |
| Free Cash Flow | $3.8B | $4.2B | -$1.4B | $1.2B | $1.3B | |
VRTX
Sector
Market Cap
$102.3B
$43.9M
Price % of 52-Week High
76.42%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
1.09%
-0.74%
1-Year Price Total Return
-0.75%
-29.11%
Beta (5-Year)
0.364
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$446.86
200-day SMA
Sell
Level
$457.21
Bollinger Bands (100)
Sell
Level
455.22 - 489.42
Chaikin Money Flow
Buy
Level
427.5M
20-day SMA
Sell
Level
$456.96
Relative Strength Index (RSI14)
Sell
Level
24.09
ADX Line
Sell
Level
13.78
Williams %R
Buy
Level
-80.3059
50-day SMA
Sell
Level
$470.34
MACD (12, 26)
Sell
Level
-11.99
25-day Aroon Oscillator
Sell
Level
-92
On Balance Volume
Neutral
Level
210.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (14.477)
Buy
CA Score
(Annual)
Level (1.941)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-4.9781)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Stock Forecast FAQ
In the current month, VRTX has received 17 Buy ratings 12 Hold ratings, and 2 Sell ratings. The VRTX average analyst price target in the past 3 months is $498.37.
-
Where Will Vertex Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Vertex Pharmaceuticals share price will rise to $498.37 per share over the next 12 months.
-
What Do Analysts Say About Vertex Pharmaceuticals?
Analysts are divided on their view about Vertex Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Vertex Pharmaceuticals is a Sell and believe this share price will drop from its current level to $325.00.
-
What Is Vertex Pharmaceuticals's Price Target?
The price target for Vertex Pharmaceuticals over the next 1-year time period is forecast to be $498.37 according to 31 Wall Street analysts, 17 of them rate the stock a Buy, 2 rate the stock a Sell, and 12 analysts rate the stock a Hold.
-
Is VRTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Vertex Pharmaceuticals is a Buy. 17 of 31 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of VRTX?
You can purchase shares of Vertex Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Vertex Pharmaceuticals shares.
-
What Is The Vertex Pharmaceuticals Share Price Today?
Vertex Pharmaceuticals was last trading at $401.14 per share. This represents the most recent stock quote for Vertex Pharmaceuticals. Yesterday, Vertex Pharmaceuticals closed at $397.27 per share.
-
How To Buy Vertex Pharmaceuticals Stock Online?
In order to purchase Vertex Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 1.63% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 7.45% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.7% over the past day.
